Antibacterial combination could fight drug-resistant tuberculosis

August 30, 2017

Pairing the antibiotic ceftazidime with the enzyme inhibitor avibactam may be an effective treatment for drug-resistant tuberculosis, a new study reports. This antibacterial drug combination - already in clinical use for Gram-negative bacterial infections - could aid in stemming the growing global drug-resistant tuberculosis crisis. Mycobacterium tuberculosis (or Mtb) causes one of the world's deadliest diseases. According to the World Health Organization, 10.4 million people contracted Mtb and 1.8 million died from the disease in 2015. While newer antibiotics like bedaquiline and delamanid have improved patient outcomes, they are still associated with a 24-month treatment failure rate of 38% in those with extensively drug-resistant Mtb. Searching for a much-needed path to immediately deploy new treatments (compared to the often decade-long path to approval that most experimental agents under investigation face), Deyvani Deshpande and colleagues examined the unexploited Mtb-fighting potential of currently marketed compounds. They studied commercially available CAV (a duo of ceftazidime and avibactam) and compared its effectiveness to other first-line regimens using a screening tool endorsed by the FDA (called the hollow fiber system model, which allows for a quick examination of drug efficacy based on human lung pharmacokinetics). With computer-aided simulations, they identified optimal CAV doses based on body weight in adults and young children. Deshpande et al. say that CAV could be a safer option for pregnant women and HIV-infected patients, and that clinical trials are the next step to test the drug combination. The authors' approach could be used to accelerate the identification of other promising antibiotic candidates - in months rather than years.
-end-


American Association for the Advancement of Science

Related Drug Combination Articles from Brightsurf:

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Montefiore and Einstein test a new drug combination to conquer COVID-19
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection.

New drug combination passes safety test in pancreatic cancer
A new study has shown a novel peptide antagonist, given in combination with a PD-1 inhibitor, to be safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer.

Three-drug combination reduces COPD patient mortality
Once-daily treatment of patients with chronic obstructive pulmonary disease (COPD) with an inhaler combining fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) reduced all-cause mortality by 42 percent, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

New drug combination could support better cancer treatments
Researchers have identified a promising new drug combination that could significantly help the immune system target cancer cells and kill them.

Drug combination reverses hypersensitivity to noise
MIT neuroscientists have identified two brain circuits that help to tune out distracting sensory information, and showed that enhancing the activity of those circuits in mice could reverse noise hypersensitivity, a common symptom of autism.

Fruit flies live longer with combination drug treatment
A triple drug combination has been used to extend the lifespan of fruit flies by 48% in a new study led by UCL and the Max Planck Institute for Biology of Ageing, and published in Proceedings of the National Academy of Sciences (PNAS),

Little-used drug combination may extend the lives of lung transplant patients
Median survival after lung transplant is less than six years.

Novel combination of drugs may overcome drug-resistant cancer cells
A new study led by investigators from Brigham and Women's Hospital suggests that a combination of three drugs, including a new class of glucose-6-phosphate dehydrogenase inhibitors, could overcome cross-therapy resistance.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Read More: Drug Combination News and Drug Combination Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.